Literature DB >> 33799309

Hollow mesoporous polydopamine nanospheres: synthesis, biocompatibility and drug delivery.

Kunpeng Lin1, Ying Gan1, Peide Zhu1, Shanshan Li1, Chen Lin1, Shuling Yu1, Shuang Zhao1, Jiahua Shi1, Runming Li2, Jinfang Yuan2.   

Abstract

Various polydopamine (PDA) nanospheres were synthesized by utilizing triblock copolymer Pluronic F127 and 1,3,5-trimethylbenzene (TMB) as soft templates. Precise morphology control of polydopamine nanospheres was realized from solid polydopamine nanospheres to hollow polydopamine nanospheres, mesoporous polydopamine nanospheres and hollow mesoporous polydopamine nanospheres (H-MPDANSs) by adjusting the weight ratio of TMB to F127. The inner diameter of the prepared H-MPDANSs can be controlled in the range of 50-100 nm, and the outer diameter is about 180 nm. Furthermore, the thickness of hollow mesoporous spherical shell can be adjusted by changing the amount of dopamine (DA). The H-MPDANSs have good biocompatibility, excellent photothermal properties, high drug loading capacity, and outstanding sustainable drug release properties. In addition, both NIR laser irradiation and acid pH can facilitate the controlled release of doxorubicin (DOX) from H-MPDANSs@DOX.
© 2021 IOP Publishing Ltd.

Entities:  

Keywords:  biocompatibility; drug delivery; hollow mesoporous nanospheres; polydopamine; polydopamine nanospheres

Year:  2021        PMID: 33799309     DOI: 10.1088/1361-6528/abf4a9

Source DB:  PubMed          Journal:  Nanotechnology        ISSN: 0957-4484            Impact factor:   3.874


  3 in total

Review 1.  Manganese-based hollow nanoplatforms for MR imaging-guided cancer therapies.

Authors:  Shuang Liang; Guangfu Liao; Wenzhen Zhu; Li Zhang
Journal:  Biomater Res       Date:  2022-07-06

Review 2.  Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranostics.

Authors:  Menglu Zhu; Yi Shi; Yifan Shan; Junyan Guo; Xuelong Song; Yuhua Wu; Miaolian Wu; Yan Lu; Wei Chen; Xiaoling Xu; Longguang Tang
Journal:  J Nanobiotechnology       Date:  2021-11-24       Impact factor: 10.435

3.  Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy.

Authors:  Qi Fang; Shaoyu Liu; Jiangyu Cui; Ruiyue Zhao; Qian Han; Peng Hou; Youcai Li; Jie Lv; Xiaoyao Zhang; Qun Luo; Xinlu Wang
Journal:  Front Bioeng Biotechnol       Date:  2022-07-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.